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Glucose hypometabolism and impaired mitochondrial function in neurons have been 21	
  
suggested to play early and perhaps causative roles in Alzheimer’s disease (AD) 22	
  
pathogenesis. Activity of the aspartic acid protease, beta-site amyloid precursor protein 23	
  
(APP) cleaving enzyme 1 (BACE1), responsible for beta amyloid peptide generation, has 24	
  
recently been demonstrated to modify glucose metabolism. We therefore examined, using a 25	
  
human neuroblastoma (SH-SY5Y) cell line, whether increased BACE1 activity is responsible 26	
  
for a reduction in cellular glucose metabolism. Overexpression of active BACE1, but not a 27	
  
protease-dead mutant BACE1, protein in SH-SY5Y cells reduced glucose oxidation and the 28	
  
basal oxygen consumption rate, which was associated with a compensatory increase in 29	
  
glycolysis. Increased BACE1 activity had no effect on the mitochondrial electron transfer 30	
  
process but was found to diminish substrate delivery to the mitochondria by inhibition of key 31	
  
mitochondrial decarboxylation reaction enzymes. This BACE1 activity-dependent deficit in 32	
  
glucose oxidation was alleviated by the presence of beta hydroxybutyrate or α-lipoic acid.  33	
  
Consequently our data indicate that raised cellular BACE1 activity drives reduced glucose 34	
  
oxidation in a human neuronal cell line through impairments in the activity of specific 35	
  
tricarboxylic acid cycle enzymes.  Because this bioenergetic deficit is recoverable by 36	
  







inhibitors, may be an effective therapeutic strategy in the early-stage management or 38	
  








Alzheimer’s disease (AD) is an age-related neurodegenerative disease, with the vast majority 43	
  
of cases described as sporadic and not currently linked with a specific gene defect.  There are 44	
  
approximately 44 million people living with AD in the world, and this number is predicted to 45	
  
increase dramatically over the next three decades, severely impacting on healthcare systems 46	
  
and the socio-economic environment.  Presently, we have a limited understanding of the early 47	
  
events in sporadic AD disease aetiology.  While the progression of AD is closely associated 48	
  
with dysfunctional tau protein and cholinergic deficits, it is generally observed by biomarker 49	
  
analysis that changes in the hallmark amyloid plaque pathology precedes these other 50	
  
pathogenic drivers [1-4].  There has also been increasing interest in the role of brain 51	
  




It has long been recognised that glucose is the predominant substrate utilised by the adult 54	
  
brain under physiological conditions [8].  Indeed, while only constituting 2% to body weight, 55	
  
the brain consumes around 20 and 25% of the total body oxygen consumption and glucose 56	
  
respectively [9].  Furthermore, the respiratory quotient of the brain is almost exactly 1, 57	
  
indicating near universal carbohydrate metabolism [10].  Although glucose is the dominant 58	
  
substrate for brain metabolic activity, alternative substrates, such as glycogen and amino 59	
  
acids can play a role in central metabolism.  However due to limited supply and storage 60	
  
capacity, this is thought to be relatively minor under physiological conditions [11].  Glucose 61	
  
metabolism in the brain is tightly coupled to the generation of intracellular adenosine 62	
  
triphosphate (ATP), largely to support neurotransmitter production and release.    63	
  
Consequently, this reliance on glucose coupled with a high-energy consumption makes the 64	
  






Brain hypometabolism is a universal change observed during Alzheimer’s disease (AD) 68	
  
progression and recently, it has been proposed to have a major causative role in AD 69	
  
pathogenesis [12,13].  Through the use of neuroimaging techniques, impaired brain glucose 70	
  
metabolism has been demonstrated to occur: before atrophy in autosomal AD cases, during 71	
  
the progression towards non-familial AD and in individuals at high risk of AD (i.e. APOE ε4 72	
  
carriers) prior to symptom manifestation [14-18].  This reduced brain glucose metabolism has 73	
  
been postulated to result from impaired mitochondrial functioning [19-21], with similar 74	
  
changes observed in a variety of transgenic mouse models of AD [7,22-24].  Recent evidence 75	
  
suggests a putative link between neuronal glucose metabolism and the presence of beta 76	
  
amyloid (Aβ) peptides, considered by many to be the primary pathogenic driver of AD.  Aβ 77	
  
peptides derive from increased cleavage of amyloid precursor protein (APP), which is 78	
  
ubiquitously expressed in tissues, with highest levels in the brain.  APP is cleaved by two 79	
  
competing enzyme processes; an alpha secretase pathway, resulting in the soluble cleaved 80	
  
product sAPPα and no Aβ production and a beta secretase pathway, which releases sAPPβ 81	
  
and following additional cleavage of the remaining protein by γ-secretase, releases Aβ. Aβ 82	
  
accumulates in the mitochondria of AD patients and AD mouse models, prior to the 83	
  







mitochondrial respiratory chain function and the activity of various mitochondrial 85	
  
dehydrogenase enzymes [28-31], indicative of an Aβ-mediated bioenergetic deficit in cells. 86	
  
Additionally, it has been shown that the hypometabolic state associated with AD may be 87	
  
driven, at least in part, by a region-specific shift in neuronal metabolism towards aerobic 88	
  
glycolysis (reduced oxidative metabolism in the presence of adequate oxygen supply; [32]).  89	
  
This switch in glucose metabolism was shown to closely correlate with Aβ deposition and 90	
  
later vulnerability to cell death during progression towards AD [33].  These findings clearly 91	
  
implicate the modulation of APP processing as a driver of the altered metabolic state 92	
  
observed in early, pre-AD states. A key enzyme driving excess Aβ production, as observed in 93	
  
AD, is the aspartyl protease, β-site APP cleaving enzyme 1 (BACE1).  BACE1 was initially 94	
  
characterised as the enzyme controlling the rate-limiting step in Aβ generation [34-36].  More 95	
  
recently however, it has also been proposed to play a role in glucose metabolism with whole 96	
  
body knock out of BACE1 resulting in improved insulin sensitivity and glucose homeostasis 97	
  
[37]. Furthermore, genetic and pharmacological manipulation of APP processing can directly 98	
  
alter glucose uptake and metabolism in the C2C12 skeletal muscle cell line [38].    99	
  
Importantly, BACE1 is a stress-sensitive protease, with oxidative, hypoxic, inflammatory and 100	
  
metabolic stress (all associated with AD initiation and/or progression) demonstrated to 101	
  
increase BACE1 levels and activity, causing APP processing to shift from the physiologically 102	
  
predominant alpha-secretase, to the beta-secretase, pathway and increasing Aβ levels.  103	
  
Indeed, recent work has demonstrated a role for oxidative, lipid and metabolic stressors in 104	
  
regulating BACE1 gene and protein expression as well as activity [39-43].  Furthermore, 105	
  
alterations in its expression result from changes in micro RNA (miR) regulation of the 5’ 106	
  
untranslated region (UTR) of BACE1 have been demonstrated in sporadic AD cases [44-46].  107	
  
Consequently, chronic stress events and altered translational regulation may in turn culminate 108	
  




   111	
  
Given that Aβ directly impairs mitochondrial enzyme function and that AD is associated with 112	
  
impaired glucose metabolism we hypothesised that manipulating APP processing through 113	
  
BACE1 overexpression in SH-SY5Y neuroblastoma cells would phenocopy the defects in 114	
  
glucose metabolism at the cellular level, allowing us to explore in more detail this initial and 115	
  










SH-SY5Y cells were cultured under aseptic conditions and maintained in a humidified 121	
  
atmosphere of 95% air and 5% CO2.  Cells were maintained in Dulbecco’s Modified Eagle’s 122	
  
Medium (DMEM) F-12 media (Gibco Life Technologies, Paisley, UK) supplemented with 123	
  
10% fetal bovine serum (Sera Laboratories, West Sussex, UK), 4 mM L-glutamine (Gibco) 124	
  
and 2% Penicillin streptomycin (100 units/ml; Gibco).  SH-SY5Y cells were transfected with 125	
  
12 µg DNA of pcDNA3.1 containing empty vector (SH-SY5YEV), full-length human BACE1 126	
  
(SH-SY5YB1), or BACE1 active site mutant (SH-SY5YmB1) using Lipofectamine 2000 127	
  
(Invitrogen Life Technologies, Paisley, UK). Stable cells were selected and lines maintained 128	
  
using 1 and 0.5 mg/ml G418 sulphate respectively (Sigma-Aldrich, Gillingham, UK) as 129	
  







concurrently produced EV controls, were used for these studies.  Prior to some glucose 131	
  
oxidation assays, cells were treated overnight, as indicated, with the pyruvate dehydrogenase 132	
  
inhibitor, dichloroacetate (DCA; Sigma-Aldrich) or growth media supplemented with α-133	
  






Full length myc-his tagged human BACE1 in pcDNA3.1 was obtained from 137	
  
GlaxoSmithKline (GSK; Harlow, UK) and mBACE1 (a kind gift from Professor Wolfe 138	
  




Immunoblotting and gene expression 141	
  
Protein isolation and immunoblotting procedures were as described previously [54].  For 142	
  
relative quantification of APP cleavage by alpha-secretase (sAPPα) versus beta-secretase 143	
  
(sAPPβ) pathways, cells were incubated for between 20-24 hours in Optimem (Gibco), and 144	
  
media concentrated (using 30 kDa Amicon Ultra 15 ml filters; Merck Millipore, Livingston, 145	
  
UK) by centrifugation (4000 x g) and subjected to SDS-PAGE with amounts presented 146	
  
relative to total protein.  Protein antibodies used were: anti-Actin (Sigma-Aldrich; 1:5000), 147	
  
anti-APP (Ab54, GSK; 1:4000), anti-sAPPα (Cambridge Bioscience, Cambridge, UK; 148	
  
1:1000), anti-sAPPβ (GSK; 1:1000), anti-BACE1 (Sigma-Aldrich; 1:1000), anti-BAD (New 149	
  
England Biolabs, Hitchin, UK; 1:1000), with anti-total PDH  (1 mg/ml) and anti-pPDHe1α (1 150	
  




Glucose oxidation assay 153	
  
SH-SY5YEV, SH-SY5YB1 or SH-SY5YmB1 cells were plated into 6-well cell culture plates 154	
  
and any pre-treatments carried out as described above and in the results section.  To begin the 155	
  
assay, cells were washed twice with Hepes-buffered saline (HBS (in mM); 140 NaCl, 20 156	
  
Hepes, 5 KCl, 2.5 MgSO4 and 1 CaCl2, pH 7.4) and incubated in HBS containing 2.5 mM 157	
  
glucose and 74 kBq/ml D-[U-14C]glucose (PerkinElmer) along with any relevant inhibitors or 158	
  
treatments indicated in the results section for 3 hours at 37 °C.  Media were transferred and 159	
  
14CO2 liberated by acidification with 60% perchloric acid, trapped by Whatman (GF/B) filter 160	
  
papers discs pre-soaked with 1 M KOH and radioactivity quantified by liquid-scintillation 161	
  
counting.  Cells from the assay were washed twice with ice-cold 0.9 % NaCl and lysed with 162	
  
1ml of 50 mM NaOH, and the radioactivity contained within the lysate quantified by liquid-163	
  
scintillation counting, which served as a measure of the 14C incorporation into the cell during 164	
  
the assay period.  Total protein content was determined in the lysate via the Bradford method 165	
  






The Seahorse Extracellular Flux Analyser utilises solid sensors that simultaneously monitor 169	
  
the oxygenation and pH of the media.  The rate of oxygen consumption (OCR) and 170	
  
extracellular acidification rates (ECAR) can therefore be assessed in near real time allowing 171	
  
for high resolution changes in a range of metabolic parameters.  SH-SY5YEV, SH-SY5YB1 or 172	
  
SH-SY5YmB1 cell monolayers were seeded into XF 24-well culture microplates (Seahorse 173	
  







results section.  Optimal cell number was determined following a cell titration assay taking 175	
  
into account oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), 176	
  
oxygen tension values and the appearance of the cell monolayers and was determined to be 177	
  
40,000 cells.   On the day of the assay, cells were placed in unbuffered DMEM with relevant 178	
  
inhibitors/treatments as indicated and placed in a non-CO2 incubator for 1 hour (to de-gas 179	
  
solutions) prior to assay initiation. Standard 3 minute mix, 2 minute wait and 3 minute 180	
  
measure cycles were used; with 5 baseline measurements taken before, and a subsequent 3 181	
  




Enzyme activity assays 184	
  
Activity assays for pyruvate dehydrogenase (PDH; Abcam, Cambridge, UK), α-ketoglutarate 185	
  
dehydrogenase (α-KGDH; Antibodies Online, Aachen, Germany), isocitrate dehydrogenase 186	
  
(IDH; Sigma-Aldrich) and fumarase (Abcam) were performed according to the 187	
  








Control, empty vector-treated (SH-SY5YEV) and BACE1 overexpressing (SH-SY5YB1) cells 192	
  
displayed equivalent APP protein levels, showing the three predominant APP transcript 193	
  
protein isoforms present in neurons ([55]; Fig. 1A,B).  As expected, SH-SY5YB1 cells 194	
  
exhibited significantly higher BACE1 protein levels (Fig. 1A,C), which resulted in altered 195	
  
APP cleavage; promoting a substantial shift from non-amyloidogenic to amyloidogenic 196	
  
processing (as denoted by increased sAPPβ and decreased sAPPα levels (Fig. 1A,D,E).   197	
  
Overexpression of BACE1 resulted in a marked reduction in the rate of 14C-glucose 198	
  
oxidation, compared to SH-SY5YEV cells (Fig. 1F), in agreement with recent findings in 199	
  
C2C12 skeletal muscle cells [34]. The decrease in glucose oxidation is not due to impaired 200	
  
glucose incorporation into the cell (Fig. 1G), and suggests that increased BACE1 protein 201	
  
levels and activity cause a fundamental change in the ability of SH-SY5Y cells to oxidise 202	
  
glucose (Fig. 1H).   203	
  
In an attempt to discern whether the changes in glucose oxidation rate were dependent upon 204	
  
the secretase activity of BACE1, a concomitant group of cells that overexpress a mutant form 205	
  
of BACE1, devoid of secretase activity (SH-SY5YmB1; [56]) were examined.  BACE1 protein 206	
  
levels in SH-SY5YmB1 cells were raised to a similar extent to that observed for SH-SY5YB1 207	
  
cells, with no alteration in APP protein levels (Fig. 2A-C). Interestingly, the overexpression 208	
  
of the secretase-dead BACE1 mutant exerted a dominant negative effect over APP processing 209	
  
with reduced sAPPβ release, compared with SH-SY5YB1 and SH-SY5YmB1 cells, into the 210	
  
culture media (Fig. 2A,D).  The reduced β-secretase cleavage of APP in the presence of 211	
  
mBACE1 was also mirrored in its effect on glucose oxidation rate, with no reduction in 212	
  
glucose oxidation concomitant with comparable glucose incorporation between cell types 213	
  
(Fig. 2E,F), indicating that increased BACE1 activity is required to depress glucose oxidation 214	
  











The cellular pathways that facilitate glucose metabolism are glycolysis (and the pentose 218	
  
phosphate pathway), which occurs in the cytoplasm and the TCA cycle and oxidative 219	
  
phosphorylation, which are present in the matrix and inner mitochondrial membrane, 220	
  
respectively. Actively respiring mitochondria consume oxygen and therefore oxygen 221	
  
consumption rate (OCR) can be taken as a measure of substrate flux through the oxidative 222	
  
phosphorylation pathway while extracellular acidification rate (ECAR) reflects the release of 223	
  
lactate (lactic acid) converted from pyruvate following glycolysis. SH-SY5YB1 cells exhibit 224	
  
decreased OCR concurrent with increased ECAR in comparison to SH-SY5YEV cells (Fig. 225	
  
3A,B).  Taken together these changes reflect a robust shift between these metabolic processes 226	
  
as shown by the change in the ratio of oxidative phosphorylation to glycolytic metabolism in 227	
  
cells with increased BACE1 activity (Fig. 3C).   228	
  
To further investigate these changes, a glycolysis stress test (which assesses basal glycolysis, 229	
  
glycolytic capacity and glycolytic reserve) was performed (Fig. 3D).  SH-SY5YEV and SH-230	
  
SY5YB1 cells were incubated in media containing zero glucose, 2.5 mM pyruvate and 4 mM 231	
  
L-glutamine for 100 minutes, following which stimulation of basal glycolysis was achieved 232	
  
by the injection of 2.5 mM glucose into the assay media.  The increase in basal ECAR was 233	
  
significantly higher in SH-SY5YB1 cells, compared to control cells, indicating that the raised 234	
  
BACE1 activity augmented aerobic glycolysis (Fig. 3E).  Inhibition of F1F0 ATP synthase by 235	
  
oligomycin leaves cells wholly reliant on glycolysis for ATP generation (termed maximal 236	
  
glycolysis).  This rate was also significantly increased in SH-SY5YB1, compared to control, 237	
  
cells following BACE1 overexpression (Fig. 3F).  Finally, the cellular glycolytic reserve is 238	
  
given by the difference between basal and maximal glycolysis, with a significantly higher 239	
  
glycolytic reserve observed in the SH-SY5YB1 cells (Fig. 3G).  Collectively, these data 240	
  
indicate that raised BACE1 activity depresses glucose oxidation in SH-SY5Y cells and, as a 241	
  




Mitochondrial efficiency is unaltered by raised BACE1 activity in SH-SY5Y cells   244	
  
The marked reduction in oxidative phosphorylation, concurrent with increased glycolytic 245	
  
metabolism in SH-SY5YB1 cells, indicated that increased BACE1 activity reduced substrate 246	
  
delivery to the mitochondria and/or impaired mitochondrial function.  To test mitochondrial 247	
  
efficiency in these cells, a modified Mitochondrial Stress Test (Seahorse Bioscience) protocol 248	
  
was utilised.  As previously reported, a limited maximal respiration rate is achievable in 249	
  
undifferentiated SH-SY5Y cells [57] in the absence of pyruvate in the assay media. 250	
  
Consequently, we therefore performed a split assay to investigate the effects of mitochondrial 251	
  
metabolism perturbation: the first part measuring the proportion of respiration dedicated to 252	
  
ATP generation (ATP synthase inhibition with oligomycin), the maintenance of 253	
  
mitochondrial leak (a combination of rotenone (complex I inhibition) and antimycin A 254	
  
(complex III inhibition) to minimize mitochondrial respiration) and the relative contribution 255	
  
of non-mitochondrial OCR (Fig. 4A).  However, increased BACE1 activity in SH-SY5Y 256	
  
cells had no effect on any of these oxidative parameters (Fig. 4B-D).  The second part 257	
  
encompasses a test of the cellular reserve capacity via the induction of maximal respiration 258	
  
through addition of the proton ionophore FCCP.  This drug collapses the mitochondrial 259	
  
membrane potential, leading to uncoupled (no ATP generation) substrate flux through the 260	
  
mitochondria, promoting an increase in glycolysis in an attempt to maintain intracellular ATP 261	
  
levels.  Raised BACE1 activity also had no effect on SH-SY5Y mitochondrial reserve 262	
  
capacity (Fig. 4E,F).  The results from these assays show that chronic elevation of BACE1 263	
  







Consequently, this result strongly indicated that the BACE1 activity-driven decrease in 265	
  




Raised BACE1 activity lesions key metabolic pathways in oxidative glucose metabolism 268	
  
There are three key control points involved in the regulation of neuronal metabolism, these 269	
  
are the generation of glucose-6-phosphate, pyruvate and acetyl CoA.  In neurons, pyruvate is 270	
  
predominantly produced directly from metabolism of glucose or indirectly, through the 271	
  
provision of extracellular lactate via the astrocyte-neuron lactate shuttle [58,59].  Therefore, 272	
  
in an attempt to better understand the changes in cellular metabolism induced by increased 273	
  
BACE1 activity, lactate utilisation by SH-SY5Y cells was assessed.  SH-SY5YB1 cells 274	
  
displayed significantly reduced lactate consumption as assessed by the ability of lactate to 275	
  
repress 14C-labelled glucose oxidation (Fig. 5A).  This deficit could also be observed as a 276	
  
reduction in OCR when cells were provided physiological concentrations (0.5 or 2 mM; [60]) 277	
  
of lactate as sole substrate, although the reduction in lactate metabolism was overcome by the 278	
  
presentation of a higher (4 mM) lactate concentration (Fig. 5A,B).  As the oxidation of both 279	
  
glucose and lactate was diminished, we hypothesised that raised BACE1 activity resulted in 280	
  
impairment of the pyruvate dehydrogenase complex activity (PDH).  To address this we used 281	
  
an indirect PDH activity assay and demonstrated that SH-SY5YB1 cells displayed a marked 282	
  
reduction of PDH activity (Fig. 5C).  Consistent with this outcome, SH-SY5YB1 cells 283	
  




In response to cellular injury or stress, compensatory metabolic strategies are employed in an 286	
  
attempt to bypass reduced glucose utilization associated with decreased PDH activity and 287	
  
obviate impaired mitochondrial TCA function.  For example, glutamine metabolism is 288	
  
diverted from an oxidative to reductive route [61,62], causing increased conversion to 289	
  
glutamate and, through glutamate dehydrogenase, raised levels of α-ketoglutarate.  This 290	
  
additional source of α-ketoglutarate should supplement ATP generation through the TCA 291	
  
cycle as it bypasses the block at PDH.  Consequently, we examined whether such an 292	
  
alternative route for TCA substrate replenishment was capable of recovering oxidative 293	
  
metabolism. Thus OCR and ECAR were measured when SH-SY5YEV and SH-SY5YB1 cells 294	
  
were provided glucose (2.5 mM) alone or glucose (2.5 mM) + glutamine (4 mM).  However, 295	
  
the presence of glutamine did not affect the attenuation of OCR or enhancement of ECAR in 296	
  
SH-SY5YB1 cells (Fig. 5E). Moreover, OCR was reduced in SH-SY5YB1 cells when 297	
  
glutamine was provided as the exclusive substrate (Fig. 5F).  These data indicate that either 298	
  
glutamine does not play a significant role in SH-SY5Y basal metabolism and/or that raised 299	
  
BACE1 activity blunts additional TCA enzymes, such as α-ketoglutarate dehydrogenase (α-300	
  
KGDH), which converts α-ketoglutarate to succinyl-CoA. Indeed, SH-SY5YB1 cells showed 301	
  
a large, BACE1 secretase activity-dependent, reduction in α-KGDH activity, which is the 302	
  
rate-controlling step of the TCA cycle (Fig. 5G).   303	
  
Because PDH and α-KGDH catalyse decarboxylation reactions involved in mitochondrial 304	
  
bioenergetics, we assayed the activity of the third enzyme utilising this process, isocitrate 305	
  
dehydrogenase (IDH).  Three isoforms of IDH are present in cells, IDH3 in the mitochondrial 306	
  
matrix, which reduces NAD+ to NADH, and IDH1 (cytoplasmic and peroxisomal) and IDH2 307	
  
(mitochondrial) reducing NADP+ to NADPH.  Consequently, specific isoform function was 308	
  
determined by differential supplementation (NAD+ or NADP+) of the reaction mixes.  In 309	
  







resulted in depression of NAD+- and NADP+-dependent IHD activity (Fig. 5H). However 311	
  
impairment of TCA cycle enzyme activities by increased BACE1 activity was not universal. 312	
  
For example, although fumarase activity was reduced slightly in SH-SY5YB1 cells, this was 313	
  
matched in SH-SY5YmB1 cells, with the protein levels of fumarase also decreased in both 314	
  
these cell lines, resulting in unaltered specific activity of fumarase by raised BACE1 in SH-315	
  
SY5Y cells (Fig. 5I).  Thus manipulation of APP cleavage towards amyloidogenic processing 316	
  
by increased BACE1 activity in SH-SY5Y cells reduces the overall catabolic capacity of the 317	
  




Rescue of glucose oxidation in SH-SY5YB1 cells. 320	
  
As glutamine supplementation was unable to recover BACE1-mediated inhibition of glucose 321	
  
oxidation, we focused on PDH as a potential target for pharmacological or alternative nutrient 322	
  
interventions.  A key regulator of PDH activity is by phosphorylation of its E1α subunit [63], 323	
  
which is predominantly controlled by the inhibitory effect of pyruvate dehydrogenase kinases 324	
  
(PDKs) versus activation through de-phosphorylation by pyruvate dehydrogenase 325	
  
phosphatase (PDP).  Dichloroacetate (DCA) is a PDK1 inhibitor, which enhances oxidative 326	
  
phosphorylation in the brain [58] and has been promoted clinically for its anti-neoplastic 327	
  
effects [64].  Consistent with PDH inhibition, SH-SY5YB1 cells exhibited increased 328	
  
phosphorylation of the e1α subunit at serine 293 compared to SH-SY5YEV cells (Fig. 6A). 329	
  
Treatment with DCA (10 and 100 µM) resulted in decreased levels of Ser293 e1α 330	
  
phosphorylation of both SH-SY5Y cell types, although Ser293 e1α phosphorylation remained 331	
  
significantly higher in SH-SY5YB1 cells (Fig. 6A,B).  In agreement with the reduction in e1α 332	
  
phosphorylation, incubation of SH-SY5YEV cells with DCA (100 µM) increased the glucose 333	
  
oxidation rate (Fig. 6C). However, although glucose oxidation of SH-SY5YB1 cells was also 334	
  
enhanced by DCA treatment, this remained significantly lower than that of the SH-SY5YEV 335	
  
cells, mirroring e1α phosphorylation status. 336	
  
An alternative means of bypassing PDH is through the application of ketones, such as beta-337	
  
hydroxybutyrate (BHB), which is metabolised to acetyl-CoA and enters the TCA cycle at 338	
  
oxaloacetate. The presence of BHB (0.5 – 10 µM) recovered the relative deficit in glucose 339	
  
oxidation of SH-SY5YB1 cells, compared to SH-SY5YEV cells, in a concentration-dependent 340	
  
manner (Fig. 6D).  Previous studies [65,66] have indicated that diminished mitochondrial 341	
  
consumption of glucose in neurons and the ability to switch substrate preference to ketones is 342	
  
dependent on the presence and activity of BAD (BCL-2-associated agonist of cell death), a 343	
  
member of the BCL-2 gene family member of apoptotic control proteins, with increased 344	
  
mitochondrial usage of BHB in Bad–/– cortical neurons.  In agreement with this model, we 345	
  
find that the increased ability of SH-SY5YB1 cells to utilise BHB over SH-SY5YEV cells and 346	
  
enhance glucose oxidation, is associated with a large reduction of BAD protein expression 347	
  
(Fig. 6E).  Finally we also investigated the ability of the naturally occurring enzyme co-348	
  
factor, α-lipoic acid to modify glucose oxidation of SH-SY5YB1 cells as previous studies 349	
  
have shown this compound to up-regulate mitochondrial bioenergetics and promote glucose 350	
  
uptake [67,68].  Indeed PDH and α-KGDH protein complexes require α-lipoic acid as a co-351	
  
factor for their acyl transferase activity.  Supplementation of the growth media with α-lipoic 352	
  
acid (25 or 50 µM for 48 hours) resulted in a robust concentration-dependent attenuation of 353	
  
the impaired glucose oxidation rate displayed by SH-SY5YB1, compared to SH-SY5YEV cells 354	
  
(Fig. 6F). Taken together, these results demonstrate the applicability of alternative nutrient 355	
  
(BHB) or co-factor (α−lipoic acid) supplementation to alleviate or by-pass the impaired 356	
  











In this study we demonstrate that raised BACE1 activity by overexpression in SH-SY5Y 360	
  
cells, and subsequent modification of APP metabolism, induces a shift from the 361	
  
physiologically predominant alpha-secretase cleavage pathway to the amyloidogenic beta-362	
  
secretase cleavage pathway, which results in decreased glucose metabolism.  This 363	
  
bioenergetic impairment was dependent upon the secretase activity of BACE1 and produced 364	
  
a fundamental shift in the cellular metabolic profile, characterised by reduced glucose 365	
  
oxidation in association with a compensatory increase in glycolysis, in an attempt to maintain 366	
  
ATP production.  367	
  
Decreased brain glucose metabolism is an invariant pathophysiological event occurring in 368	
  
AD progression, and it has been hypothesised that this may occur years, and even decades 369	
  
prior to symptom presentation [15,16,69,70].  Impaired glucose metabolism has also been 370	
  
noted in central tissues taken from AD animal models [22,23,68].  Furthermore, despite the 371	
  
observation that reduced glucose metabolism is predictive of later cognitive decline and AD 372	
  
symptom presentation, relatively little is known about the cellular mechanisms underlying 373	
  
these changes.  Interestingly, the metabolic shift we have observed in favour of aerobic 374	
  
glycolysis under conditions of increased BACE1 activity mirrors early and predictive 375	
  
changes occurring in the brains of people who later develop AD.  The brain areas that display 376	
  
this profile overlap with regions showing the greatest prevalence of Aβ pathology, future 377	
  
susceptibility to cell death and are predictive of cognitive decline [32,33]. 378	
  
The mechanisms underlying glucose hypometabolism in AD are not well understood.  379	
  
However mitochondrial dysfunction has been widely reported in clinical and experimental 380	
  
AD studies [19-21] and Aβ has been reported to accumulate in the mitochondria of AD 381	
  
patients and transgenic AD mouse models prior to amyloid deposition [25-27,71].  Although 382	
  
there are numerous reports of impaired electron transfer in mitochondria, for example via 383	
  
diminished activity in complexes I to V in AD subjects [72-75], and diminished complex III 384	
  
and IV activity in a transgenic AD mouse model [76] we found no effect of raised BACE1 385	
  
activity on mitochondrial electron transfer function in SH-SY5Y cells.  It may be that 386	
  
additional injurious processes, such as increased oxidative and/or inflammatory stress are 387	
  
required to act concurrently with raised BACE1 activity and increased levels of Aβ to elicit 388	
  
this outcome.    389	
  
Thus the driving force for decreased glucose oxidation in SH-SY5YB1 cells appears to be 390	
  
through reduced substrate delivery to mitochondria by a BACE1 activity-dependent 391	
  
impairment of specific TCA cycle enzymes; PDH, αKGDH and IDH each of which utilise 392	
  
decarboxylation reactions.  Previous studies on post-mortem AD brains indicate reduced 393	
  
levels and/or activity of these key enzymes: PDH, αKGDH and IDH [20,77-81], with PDH 394	
  
and αKGDH exhibiting the largest decreases in activity. Furthermore, Aβ peptides have been 395	
  
demonstrated to inhibit PDH and αKGDH directly [28,31,82]. In contrast we find no change 396	
  
in the activity of the TCA enzyme fumarase, the activity of which is also unaltered in AD 397	
  
brains [20].  Our results add to these findings by implicating raised BACE1 activity and 398	
  
manipulation of APP processing as central to these enzyme deficits and metabolic adaptations 399	
  
at the cellular level, indicating a key role for BACE1 and its up-regulation in response to 400	
  
oxidative and inflammatory stress, which are associated with the very early stages of AD 401	
  







some of the earliest changes in glucose metabolism seen in the brain during the progression 403	
  
towards AD.   404	
  
In situations of diminished glucose utilization, there are a number of strategies that may be 405	
  
engaged in an attempt to bypass this block in metabolism.  For example, in brain ischemic-406	
  
reperfusion injury there is also decline in glucose oxidation and PDH activity [84,85]. 407	
  
Application of glutamine has been demonstrated to offer some protection against ischemic-408	
  
reperfusion injury in peripheral tissues by providing an alternative energy source for the cell 409	
  
to maintain ATP content [86,87]. In addition to providing a source of carbon for 410	
  
neurotransmitter production, glutamine can also feed into the TCA cycle and be metabolised 411	
  
to increase levels of α-ketoglutarate and succinate. However, our data demonstrate that 412	
  
glutamine supplementation is unable to restore oxidative glucose metabolism in cells 413	
  
overexpressing BACE1.  Furthermore, SH-SY5YB1 cells exhibited diminished oxidation of 414	
  
glutamine when applied as sole substrate, in line with the reduced activity of α-KGDH 415	
  
observed in these cells. 416	
  
The inhibition of PDH activity in SH-SY5YB1 cells was associated with increased 417	
  
phosphorylation of the e1α subunit at Ser293, which is the main inhibitory site for PDH 418	
  
activity [88].  Although PDK1 inhibition with dichloroacetate reduced e1α phosphorylation 419	
  
levels, this was also observed in SH-SY5YEV cells, in conjunction with a maintained relative 420	
  
lower glucose oxidation in SH-SY5YB1 cells.  This outcome may be owing to the presence of 421	
  
BACE1 activity-sensitive DCA-resistant PDK isoenzyme, or PDP, or an alternative kinase 422	
  
that phosphorylates e1α at Ser293 (e.g. GSK3).  In contrast, application of the ketone, BHB, to 423	
  
SH-SY5YB1 cells demonstrates complete recovery of glucose oxidation, relative to SH-424	
  
SY5YEV cells, presumably by directly increasing the availability of acetyl CoA to the TCA 425	
  
cycle, thus circumventing PDH.  The enhanced ability to utilise ketone bodies to aid glucose 426	
  
oxidation in SH-SY5YB1 cells may result from their reduced BAD levels, compared to SH-427	
  
SY5YEV cells.  This finding agrees with the work of Nikita Danial’s group showing that 428	
  
neurons derived from BAD knock out animals display an augmented bioenergetic profile in 429	
  
the presence of ketone bodies [66].   430	
  
α-lipoic acid is synthesised in mitochondria and is a necessary cofactor for PDH and α-431	
  
KGDH activity.  Our finding that exogenously applied α-lipoic acid also increases glucose 432	
  
oxidation in SH-SY5YB1, but not SH-SY5YEV cells suggests that raised BACE1 activity 433	
  
either reduces mitochondrial α-lipoic acid levels or lessens the ability of α-lipoic acid to 434	
  
enhance PDH and α-KGDH activity.  The latter mechanism may be favoured as there is 435	
  
evidence that excess α-lipoic acid provides protection to neuronal cells from the deleterious 436	
  
effects of exogenously applied Aβ peptides on PDH activity [89] and Aβ-induced toxicity 437	
  
[90]. Regarding the potential to reverse the metabolic deficits associated with age-dependent 438	
  
cognitive decline and early-stage or mild AD, the data presented herein demonstrate the 439	
  
capacity of α-lipoic acid and BHB to attenuate impaired glucose oxidation at a cellular level 440	
  
in face of chronically raised BACE1 activity and increased levels of Aβ peptides.  BHB and 441	
  
α-lipoic acid have been demonstrated to exhibit some positive effects on cognitive decline in 442	
  
elderly dementia and mild AD patients [11,13,91-93].  443	
  
Taken together, our findings are supportive for the rationale of targeting these TCA enzyme 444	
  
deficits in early cognitive impairment and AD.  However, so far clinical trials based on 445	
  
raising circulating levels of ketones or giving α-lipoic acid as a dietary supplement have 446	
  
provided mixed outcomes and further trials examining α-lipoic acid are currently in progress. 447	
  







of this neutraceutical approach with new therapeutics, such as BACE1 inhibitors, currently in 449	
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Figure 1:   BACE1 overexpression alters APP processing and glucose oxidation in SH-763	
  
SY5Y cells. A. Representative immunoblots showing stable overexpression of BACE1 and 764	
  
resultant changes in cellular APP and sAPPα and sAPPβ shed into the culture media, 765	
  
compared to empty vector (EV) treated controls. B. – E. SH-SY5Y BACE1 overexpression 766	
  
did not change APP protein levels (B; n =4), increased total BACE1 protein levels (c; n = 7) 767	
  
and induced a shift in APP processing, with a reduction in sAPPα (D; n = 4) and an increase 768	
  
in sAPPβ (E; n = 4). F. – H. SH-SY5Y BACE1 overexpression reduced 14C-glucose 769	
  
oxidation rate (F; n = 7), with no reduction in 14C-glucose incorporation rate (G; n = 9), 770	
  
giving an overall reduction in the ratio of 14C-glucose oxidation to incorporation (H; n = 7). 771	
  




Figure 2: Glucose oxidation in SH-SY5Y cells in not impaired following overexpression 774	
  
of secretase-dead BACE1 protein. A. Representative immunoblots showing stable 775	
  
overexpression of wild type BACE1 and a secretase-dead BACE1 mutant (mBACE1) and 776	
  
resultant changes in cellular APP and sAPPβ shed into the culture media. B. – D. SH-SY5Y 777	
  
mBACE1 overexpression increased total BACE1 to levels equivalent to BACE1 778	
  
overexpressed cells and ~3-4X greater than empty vector (EV) controls (B; n = 5), with no 779	
  
effect on APP levels (C; n = 3), but in contrast to BACE1 overexpression, mBACE1 reduced 780	
  
sAPPβ to levels below that of the EV controls (D; n = 6 – 10). E. – G. SH-SY5Y mBACE1 781	
  
overexpression had no effect on 14C-glucose oxidation compared to EV controls, in contrast 782	
  
to the reduction in 14C-glucose oxidation observed in BACE1 overexpressing cells (E; n = 5), 783	
  
with mBACE1 having no effect on 14C-glucose incorporation (F; n = 5), resulting in the ratio 784	
  
of 14C-glucose oxidation to incorporation being unchanged in mBACE1 cells (G; n = 5). 785	
  




Figure 3: BACE1 overexpression alters glucose metabolism in SH-SY5Y cells. 788	
  
A. – C. BACE1 overexpression reduces oxygen consumption rate (OCR) (A) and increases 789	
  
the extracellular acidification rate (ECAR) (B) resulting in a reduced OCR:ECAR ratio (C), 790	
  
compared to EV cells (n = 7 – 12). D. Glycolysis stress test temporal profile for EV and 791	
  
BACE1 SH-SY5Y cells showing the effects on ECAR of the sequential addition of 2.5 mM 792	
  
glucose, 1 µM oligomycin (Oligo) and 25 mM 2-deoxyglucose (2DG). E. – G. BACE1 793	
  
overexpression increased basal glycolysis (E), maximal glycolysis (F) and glycolytic reserve 794	
  
(G) compared to EV-treated cells (n = 18 – 21). Values are means ± SEM. * p < 0.05, ** p < 795	
  




Figure 4: BACE1 overexpression has no effect on ATP-linked, maximal or leak 798	
  







A. Modified mitochondrial stress temporal profile for EV and BACE1 SH-SY5Y cells 800	
  
showing the effects on the percentage change in normalised OCR of the  sequential addition 801	
  
of 1 µM oligomycin (oligo) and 2 µM rotenone and antimycin (Rot + Ant). B. – D. BACE1 802	
  
overexpression had no effect on ATP-linked OCR (B), on the OCR required to maintain the 803	
  
mitochondrial leak (C) or the non-mitochondrial OCR (D) compared to EV cells (n = 8). E. 804	
  
Temporal profile showing the normalised baseline OCR for EV and BACE1 cells and the 805	
  
maximal OCR (reserve capacity) attained following addition of 0.2 µM carboyl cyanide-p-806	
  
trifluoromethoxyphenylhydrazone (FCCP). F. BACE1 overexpression has no effect on the 807	
  
percentage OCR increase following FCCP addition compared to EV cells (n = 9-10). Values 808	
  




Figure 5: BACE1 overexpression induces specific mitochondrial TCA cycle enzyme 811	
  
lesions. A, B. SH-SY5Y cells overexpressing BACE1 exhibit reduced lactate usage at levels 812	
  
≤ 2mM compared to EV cells as demonstrated by (A) reduced repression of 14C-glucose 813	
  
oxidation (n = 6) and (B) direct OCR when lactate provided as sole substrate (n = 6 – 11). C. 814	
  
Pyruvate dehydrogenase activity (PDH) is reduced in BACE1 overexpressing, compared to 815	
  
EV, cells (n = 5).  D. OCR when EV and BACE1 cells provided 2.5 mM pyruvate as sole 816	
  
substrate (n = 5). E. OCR of EV and BACE1 SH-SY5Y cells when provided with 2.5 mM 817	
  
glucose alone or 2.5 mM glucose + 4 mM glutamine (n = 4 – 10). F. direct OCR when 4 mM 818	
  
glutamine provided as sole substrate (n = 8).  G. BACE1, but not mBACE1, overexpression, 819	
  
reduced the enzyme activity of α-KGDH, compared to EV cells (n = 6).  H. IDH activity 820	
  
(NAD+ and NADP+ isoforms) is reduced by BACE1 overexpression compared to EV cells (n 821	
  
= 4). I. BACE1 or mBACE1 overexpression has no effect on fumarase enzyme activity, 822	
  
protein levels or specific activity compared to EV cells (n = 7). Values are means ± SEM. * p 823	
  




Figure 6: Reversal of BACE1 mediated impaired glucose oxidation in SH-SY5Y cells. 826	
  
A,B. Representative immunoblots (A) of phosphorylated PDHe1α (p-PDHe1α) subunit, total 827	
  
PDHe1α and actin loading control in control (EV) and BACE1 overexpressing cells in the 828	
  
absence and presence of 10 µM or 100 µM dichloroacetate (DCA), with quantification of the 829	
  
immunoblot data shown in B (n = 4). C. DCA partially reverses BACE1 mediated 830	
  
impairment of glucose oxidation, but also increases OCR of EV cells (n = 5). D. reduced 831	
  
OCR associated with BACE1 cells is recovered to EV control levels by addition of 1 µM and 832	
  
10 µM beta hydroxybutyrate (n = 4 – 6). E. Representative immunoblots of BCL-2-833	
  
associated agonist of cell death (BAD) and actin loading control with quantification of the 834	
  
immunoblot data (n = 4). F. BACE1-mediated reduction in OCR is recovered to EV control 835	
  
levels by addition of 50 µM α-lipoic acid (n = 6). Values are means ± SEM. * p < 0.05, ** p 836	
  
< 0.01, *** p < 0.001. 837	
  
 838	
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